Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

3(38%)

Results Posted

167%(5 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_2

50%

Ph phase_4

13%

Ph phase_1

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution7 total trials

Phase 1Safety & dosage

2(28.6%)

Phase 2Efficacy & side effects

4(57.1%)

Phase 4Post-market surveillance

1(14.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(3)

Terminated(1)

Other(1)

Detailed Status

Completed3

Active, not recruiting3

unknown1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (28.6%)

Phase 24 (57.1%)

Phase 41 (14.3%)

Trials by Status

unknown113%

completed338%

terminated113%

active_not_recruiting338%

Recent Activity

3 active trials

Showing 5 of 8

active_not_recruitingphase_2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

NCT02465060

active_not_recruitingphase_2

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

NCT04439136

active_not_recruitingphase_2

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

NCT02438722

terminatedphase_2

Afatinib in Advanced Refractory Urothelial Cancer

NCT02122172

completedphase_1

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

NCT02364609

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT02465060Phase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Active Not Recruiting

NCT04439136Phase 2

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

Active Not Recruiting

NCT02438722Phase 2

S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer

Active Not Recruiting

NCT02122172Phase 2

Afatinib in Advanced Refractory Urothelial Cancer

Terminated

NCT02364609Phase 1

Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib

Completed

NCT02451553Phase 1

Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer

Completed

NCT04814056Phase 4

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion